Anti-Müllerian hormone (AMH), secreted by the ovary at decreasing levels with age, is a good quantitative marker of ovarian reserve and a predictor of follicular response to controlled ovarian hyperstimulation (COH) treatments. Although its plasma levels are related to the number of oocytes remaining in the ovary, they are not directly associated with the pregnancy rate as they do not reflect oocyte quality, which decreases significantly after the age of 35 years regardless of the ovarian reserve of the patients.

Thus, with significant controversy, the current literature questions the usefulness of AMH as a predictor of success in natural fertility or artificial insemination (AI) where we only work with 1-2 follicles (and the quantity is not so important).


Prospective study on the usefulness of AMH as a predictive marker of cumulative pregnancy rate after 4 cycles of donor AI in non-sterile women with plasma AMH values > and <1.1 ng/mL. Our hypothesis is that AMH is not related to reproductive prognosis in these cases.

Establishing or discarding this association would allow us to establish more accurate prognoses of AI cycles in our centre and therefore adapt the indication of the technique.

The study included all patients between 25 and 39 years of age who were going to undergo DAI treatment, either due to severe oligoasthenoteratozoospermia of the couple or for social reasons, counting up to 4 attempts. Patients with BMI >30, sterility due to bilateral tubal factor and/or grade II-IV endometriosis are excluded.


The study is currently in the development and research phase.


The study is currently in the development and research phase.